儿童急性淋巴细胞白血病缓解、治疗失败与复发的国际共识
Ponte-di-Legno联盟比较了近期儿童ALL临床试验中完全缓解、治疗失败和复发的定义,发现存在显著异质性,尤其是治疗失败的定义。国际主要ALL临床试验组代表召开会议制定共识定义,以标准化疗效评价并促进跨试验比较。
要点
- 完全缓解应在不早于诱导结束的时间点定义,需骨髓和外髓部位原始细胞低于特定阈值并整合MRD。
- 治疗失败定义为在预设时间点未达到完全缓解。
- 复发仅见于已获完全缓解者,需骨髓白血病细胞特定阈值经MRD确认、中枢神经系统白血病或髓外病变证据。
核心结论
- 共识定义了儿童ALL的完全缓解、治疗失败和复发,以标准化疗效评价并促进国际试验比较。
研究设计与样本
- 国际共识制定:收集近期和当前儿童ALL临床试验的疗效定义,由主要国际ALL试验组代表开会建立共识。
主要发现
- 近期和当前儿童ALL试验对完全缓解、治疗失败和复发的定义存在显著异质性,尤以治疗失败为著。
- 反应评价的关键组成包括时间、解剖部位、检测方法和阈值。
关键数值与推荐
- 完全缓解应在不早于诱导结束的时间点评估,需骨髓和外髓部位原始细胞低于特定阈值并整合MRD技术。
- 治疗失败为未在预设时间点达到完全缓解。
- 复发仅限已获完全缓解者,需骨髓白血病细胞特定阈值经MRD确认、中枢神经系统白血病或髓外病变证据。
- 治疗失败和复发的定义应与复发/难治性ALL临床试验的入组标准协调。
临床怎么用
- 临床和试验中采用统一共识定义评价完全缓解、治疗失败和复发,以便跨试验比较结局。
- 骨髓评价应整合MRD技术,并注意评估时间不早于诱导结束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comparison of treatment strategies in de novo pediatric acute lymphoblastic leukemia (ALL) requires standardized measures of efficacy. Key parameters that define disease-related events, including complete remission (CR), treatment failure (TF; not achieving CR), and relapse (loss of CR) require an updated consensus incorporating modern diagnostics. We collected the definitions of CR, TF, and relapse from recent and current pediatric clinical trials for the treatment of ALL, including the key components of response evaluation (timing, anatomic sites, detection methods, and thresholds) and found significant heterogeneity, most notably in the definition of TF. Representatives of the major international ALL clinical trial groups convened to establish consensus definitions. CR should be defined at a time point no earlier than at the end of induction and should include the reduction of blasts below a specific threshold in bone marrow and extramedullary sites, incorporating minimal residual disease (MRD) techniques for marrow evaluations. TF should be defined as failure to achieve CR by a prespecified time point in therapy. Relapse can only be defined in patients who have achieved CR and must include a specific threshold of leukemic cells in the bone marrow confirmed by MRD, the detection of central nervous system leukemia, or documentation of extramedullary disease. Definitions of TF and relapse should harmonize with eligibility criteria for clinical trials in relapsed/refractory ALL. These consensus definitions will enhance the ability to compare outcomes across pediatric ALL trials and facilitate development of future international collaborative trials.
引用
- Buchmann S, Schrappe M, Baruchel A, et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022. PMID: 34192312. doi:10.1182/blood.2021012328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。